Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) and their connected persons, specifically regarding equity awards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider equity transactions and does not contain financial performance data.
Material Changes
On February 22, 2010, a connected person of Dr. M. Slaoui received the following equity awards:
- Share Options: 5,940 ADSs under the GlaxoSmithKline 2009 Share Option Plan.
- Share Value Plan: 1,490 ADSs under the GlaxoSmithKline 2009 Share Value Plan.
- Performance Shares: 2,620 ADSs under the GlaxoSmithKline 2009 Performance Share Plan.
The share options were granted with an exercise price of US$37.32 per ADS.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or risk factors. It notes that the vesting date for all awards is February 21, 2013. The Performance Share Plan award is contingent upon the Remuneration Committee determining that performance conditions have been satisfied.
Investor Verification Checklist
- Verify the total number of ADSs awarded to Dr. Slaoui's connected person (10,050 total).
- Confirm the exercise price of US$37.32 per ADS for the share options.
- Note the vesting date of February 21, 2013, and the performance conditions attached to the Performance Share Plan.
- Recognize that this filing does not reflect the company's operational or financial results for the period.